IVD Registration Compared: FDA 809, EU IVDR, China, Brazil & India

Five IVD Regimes, Five Classification Schemes — The Same Assay Files Differently Everywhere

An in vitro diagnostic (IVD) reagent or instrument is not "registered" the same way in any two of these five markets. Each legal text sets its own risk-class scheme, its own pathway (self-certification, notification, registration, or filing), and its own reviewer. The five instruments compared here are the FDA's IVD product rule (21 CFR Part 809), the EU IVDR (Regulation (EU) 2017/746), China's Provisions for IVD Reagent Registration and Filing (SAMR Decree No. 48, 2021), Brazil's IVD resolution (ANVISA RDC 830/2023), and India's Medical Devices Rules 2017 (CDSCO). The single most dangerous assumption a global IVD manufacturer can make is that "Class II" or "Class C" means the same thing across borders — it does not, and the filing object attached to each label is different.

This is a regulatory-research comparison for compliance planning, not legal advice for a specific product. Verify every hook against the official text listed at the end.

Side-by-Side: Classification, Pathway, and Reviewer

FDA: 21 CFR Part 809 — IVDs Are Devices, Plus a CLIA Layer

Under US law an IVD is a device — defined in §809.3 — so it inherits the full device framework, with an IVD-specific labeling layer on top.

• §809.3 (definition): IVD products are reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health; intended for use in the collection, preparation, and examination of specimens taken from the human body.
• §809.10 (labeling): the IVD-specific labeling rule — proprietary/established name, intended use, storage, procedural limitations, performance, and a "date of issuance of the last revision"; §809.10(c) covers RUO / IUO ("For Research Use Only" / "For Investigational Use Only") labeling; §809.10(e) covers Analyte Specific Reagents (ASRs).
• Marketing pathways (not in Part 809 itself): most IVDs enter via 510(k) premarket notification, De Novo, or PMA (Class III, e.g., high-risk companion diagnostics); many Class I and some Class II IVDs are 510(k)-exempt but still require establishment registration, device listing (Part 807), QSR compliance (Part 820), and MDR (Part 803).
• CLIA categorization: separately, each waived or moderate-complexity test is categorized under the Clinical Laboratory Improvement Amendments for laboratory use — a second classification axis that does not exist in the same form in the other four markets.

Cross-market trap: the US "class" (I/II/III) governs the marketing pathway, but the CLIA category (waived / moderate / high complexity) governs where and by whom the test can be run — a manufacturer that registers the device but ignores the CLIA categorization loses the point-of-care / waived market. RUO-labeled products (§809.10(c)) cannot be used for clinical diagnosis, a restriction absent in some peer regimes.

EU IVDR: 2017/746 and the 80–90% Notified-Body Shift

The IVDR (in full application since 26 May 2022) replaced the IVDD and moved the large majority of IVDs from self-certification into Notified Body conformity assessment.

• Classification (Annex VIII): IVDs are sorted into Class A / B / C / D by seven rules, based on individual risk and public-health risk; Class D is the highest (e.g., blood-screening agents for HIV/HBV/HCV, blood-grouping).
• Self-certification: only Class A non-sterile devices may self-affix the CE mark without a Notified Body. Class A sterile, B, C, and D all require a Notified Body conformity assessment (Annexes IX, X, XI); Class D additionally involves an EU Reference Laboratory.
• Scale: roughly 80–90% of IVDs now require a Notified Body certificate (versus ~20% under the old IVDD) — the single biggest operational change versus the directive.
• Systemic duties: a Person Responsible for Regulatory Compliance (PRRC), a QMS with risk management, performance evaluation (Annex XIII), post-market surveillance / performance follow-up, Basic UDI-DI, and registration of manufacturer, authorized representative, and device in EUDAMED.
• Vigilance: Article 82 mirrors the MDR's 2/10/15-day serious-incident clocks (see our adverse-event comparison).

Cross-market trap: an IVD that was self-certified as a "general IVD" under the IVDD is very often a Class C under the IVDR (e.g., a cancer assay now requiring a Notified Body). Manufacturers relying on an old IVDD certificate must re-classify before the IVDR transition deadlines expire — the device's legal class has changed even though the assay has not.

China: SAMR Decree No. 48 — Filing for Class I, Registration for II/III

China regulates IVD reagents under a dedicated department rule (SAMR Decree No. 48, Provisions for In-vitro Diagnostic Reagent Registration and Filing, effective 1 October 2021), sitting under the overarching medical-device administration regulation (Decree No. 739).

• Article 6 — filing vs. registration: Class I IVD reagents are subject to filing administration (Bei'an); Class II and III are subject to registration administration (a Medical Device Registration Certificate is issued after approval).
• Where you file (by origin and class): domestic Class I — file at the city-level drug regulatory department; domestic Class II — reviewed by the provincial drug regulatory department; domestic Class III and imported Class II/III — reviewed by the NMPA, with technical review by the CMDE; imported Class I — filed with the NMPA.
• Classification catalogue: IVDs sit in Category 21 (in vitro diagnostic reagents) and Category 22 (in vitro diagnostic instruments/equipment). Classification by risk: Class I < II < III.
• New / unlisted products: a reagent not yet in the classification catalogue may be applied for directly as Class III, or the applicant may seek class confirmation from the NMPA (Article 63).
• Clinical data: Class II/III reagents may avoid clinical trials if they are on the NMPA clinical-trial-exempt catalogue (comparison study against approved equivalents or gold standards suffices); otherwise a China clinical trial or an accepted overseas-clinical-data pathway applies.

Cross-market trap: China's Class I/II/III scheme for IVDs is not the EU's A/B/C/D and not the FDA's I/II/III — a Chinese "Class II" clinical-chemistry reagent has no automatic EU or US equivalent. And the reviewer is origin-dependent: the same imported Class II reagent goes to NMPA/CMDE, while a domestic Class II goes to the province — two different timelines and feedback cultures for what is nominally the same class.

Brazil: ANVISA RDC 830/2023 — Notification for I/II, Registro for III/IV

Brazil's consolidated IVD resolution (RDC 830/2023, effective 1 June 2024, replacing RDC 36/2015) aligns its class scheme with the IVDR and IMDRF — but uses Roman numerals and a different split between the light and heavy regime.

• Article 5 — classes: IVDs are classified I, II, III, IV by intrinsic risk to user, patient, and public health — Class I (low/low) through Class IV (high/high).
• Article 6 — notification: Classes I and II are subject to notification (notificação).
• Article 7 — marketing authorization: Classes III and IV are subject to marketing authorization (registro).
• Annex I — eight classification rules: the highest applicable rule governs; self-tests are generally Class C-equivalent (here, typically III); companion diagnostics typically map to the higher band.
• Alignment: RDC 830/2023 deliberately mirrors the EU IVDR and IMDRF guidance, and up-classifications versus the old RDC 36/2015 are common — ANVISA publishes guidance on IVDs whose risk class has changed and will not individually notify manufacturers, who must self-review.
• Adjacent rules: essential safety and performance are governed by RDC 848/2024 (which also applies to IVDs), and IVD software-as-a-medical-device by RDC 657/2022.

Cross-market trap: Brazil's Class I/II/III/IV numerals are coincidentally the same labels as China's, but the regime split is different — Brazil draws the line at II/III (notification vs registro), China draws it at I/II (filing vs registration). A manufacturer that maps "Brazilian Class II = Chinese Class II = EU Class B" by the number alone will pick the wrong filing object in every market. Factor in the BRH dependency and B-GMP (RDC 665/2022) certificate for any Brazilian filing.

India: CDSCO Medical Devices Rules 2017 — A/B/C/D, Imported via Form MD 15

India regulates IVDs under the Medical Devices Rules 2017 (G.S.R. 78(E)) — and, distinctively, treats them as drugs under the Drugs and Cosmetics Act for import, manufacture, sale, and distribution.

• Rule 4(2) — classification: in vitro diagnostic medical devices are classified A / B / C / D on the basis of the risk parameters in Part II of the First Schedule (low / low-moderate / moderate-high / high), mirroring the IMDRF scheme used by the EU.
• Rule 4(3): the Central Licensing Authority (CLA) classifies a device based on its intended use and the First-Schedule parameters.
• Import object: every imported IVD test kit requires an Import Licence (Form MD 15) before importation — supported by a full technical dossier; the 2017 rules significantly expanded the set of IVDs requiring complete documentation.
• Manufacturing / audit: Class A/B manufacturing licences are granted with a notified-body audit of the manufacturing site; Class C/D involve CLA scrutiny. CDSCO's IVD/Misc/196/2020 notice gives the operative classification list, periodically updated.
• Performance evaluation: clinical performance evaluation of a new IVD requires a separate permission, with CDSCO-empanelled laboratories.

Cross-market trap: India's A/B/C/D labels match the EU's labels but the filing object is different — there is no "CE self-certification" equivalent for Class A; an imported Class A IVD still needs a Form MD 15 import licence and a notified-body manufacturing audit. And because IVDs are drugs in India, the competent authority is CDSCO's drug-regulation apparatus, not a standalone device regulator — a structural difference that affects dossier format, fees, and inspection expectations.

What to Verify in the Original Text

• 21 CFR Part 809 — §809.3 (IVD definition), §809.10(a)–(e) (labeling, RUO/IUO, ASR): confirm the IVD-specific labeling layer and the RUO prohibition on clinical use; then cross-reference the marketing pathways (510(k), De Novo, PMA), classification (Part 860, panels §862–§892), and the separate CLIA waived/moderate/high categorization.
• Regulation (EU) 2017/746 — Annex VIII (7 classification rules), Annex IX/X/XI (conformity assessment), Annex XIII (performance evaluation): confirm that only Class A non-sterile self-certifies, that ~80–90% need a Notified Body, and that Class D also involves an EU Reference Laboratory; check the current transition deadlines for legacy IVDD devices.
• SAMR Decree No. 48 (2021) — Articles 6, 10, 63, and the classification catalogue (Cat. 21/22): confirm the filing (Class I) vs. registration (II/III) split and the origin-based reviewer (city / provincial / NMPA-CMDE); read it alongside Decree No. 739 and the NMPA clinical-trial-exempt catalogue.
• ANVISA RDC 830/2023 — Articles 5, 6, 7, 8/9, Annex I (8 rules): confirm the I/II/III/IV classes, the notification (I/II) vs. registro (III/IV) split, and that up-classifications versus RDC 36/2015 are self-service; pull RDC 848/2024 (essential principles) and RDC 665/2022 (B-GMP) for the adjacent duties.
• CDSCO Medical Devices Rules 2017 — Rule 4(2)/(3), First Schedule Part II, and the Form MD 15 import licence: confirm the A/B/C/D IVD classes, the drug-based legal treatment, and the notified-body manufacturing-audit requirement; check the current IVD/Misc/196/2020 classification list for your specific analyte.

Practical Implications for a Global IVD Launch

The same assay will carry a different legal class, a different filing object, and a different reviewer in each market, and the label numbers collide: the EU and India use A/B/C/D with different filing objects, China and Brazil both use Class I/II/III/IV but draw the light/heavy line in different places, and the US layers a CLIA category on top of its device class. For a global launch, the binding planning constraints are: (1) re-classify de novo in every market — never inherit a class across borders by name; (2) secure the Notified Body (EU), NMPA/CMDE (China), BRH + B-GMP (Brazil), Form MD 15 + notified-body audit (India), and establishment registration / 510(k) or PMA + CLIA (US) as independent work-streams with non-interchangeable timelines; and (3) watch the active transition deadlines — the EU IVDR and Brazil RDC 830 have both forced re-classification and re-certification of devices whose assays never changed but whose legal class did. Build a single IVD classification matrix that lists, per market: the legal instrument, the class label, the filing object, the reviewer, and the current transition status — and treat each cell as a separate regulatory project.

Sources

• US FDA / eCFR, 21 CFR Part 809 — In Vitro Diagnostic Products for Human Use (§809.3 definition, §809.10 labeling): https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-809 ; FDA, Overview of IVD Regulation: https://www.fda.gov/medical-devices/ivd-regulatory-assistance/overview-ivd-regulation
• European Union, Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), Annex VIII (classification), Annexes IX/X/XI (conformity assessment): https://eur-lex.europa.eu/eli/reg/2017/746/oj
• China NMPA, Provisions for In-vitro Diagnostic Reagent Registration and Filing (SAMR Decree No. 48, 2021), English text: https://english.nmpa.gov.cn/2024-06/05/c_1049322.htm ; SAMR legal-text database (original): https://sjfg.samr.gov.cn/law/file/pdf/3235243/1663646614120.pdf
• ANVISA, Resolução RDC nº 830, de 6 de dezembro de 2023 — classificação, notificação e registro de produtos para saúde para diagnóstico in vitro (English version): https://www.gov.br/anvisa/pt-br/assuntos/produtosparasaude/temas-em-destaque/arquivos/2024/rdc-830-2023-en.pdf ; DOU: https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-830-de-6-de-dezembro-de-2023-529557724
• CDSCO, Medical Devices Rules, 2017 (G.S.R. 78(E)), Rule 4 and First Schedule Part II: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2022/m_device/Medical%20Devices%20Rules,%202017.pdf ; Classification of Medical Devices and IVDs under the Medical Devices Rules, 2017: https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/medical-device/Classificationg1.pdf